Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 520 entries
View as:

Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

Phase: N/A Priority: Normal
NCT ID: NCT00325416 Org: User:
Start: 11/19/01 End: 01/30/18 Due: 01/30/19

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03656133 Org: User:
Start: 09/26/18 End: 03/26/24 Due: 03/26/25

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06734130 Org: User:
Start: 01/10/25 End: 01/31/27 Due: 01/31/28

Evaluating Stress Management Among Allogeneic HCT Caregivers

Phase: N/A Priority: Normal
NCT ID: NCT05078229 Org: User:
Start: 09/16/21 End: 03/31/26 Due: 03/31/27

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00100906 Org: User:
Start: 08/31/04 End: 07/31/13 Due: 07/31/14

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT00985777 Org: User:
Start: 09/30/09 End: 02/29/16 Due: 02/28/17

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02063724 Org: User:
Start: 10/01/14 End: 09/30/22 Due: 09/30/23

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

Phase: N/A Priority: Normal
NCT ID: NCT04257474 Org: User:
Start: 01/30/20 End: 01/19/22 Due: 01/19/23

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00358319 Org: User:
Start: 03/31/05 End: 04/30/07 Due: 04/30/08

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Phase: N/A Priority: Normal
NCT ID: NCT05664178 Org: User:
Start: 02/20/23 End: 08/22/26 Due: 08/22/27

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Phase: N/A Priority: Normal
NCT ID: NCT06553872 Org: User:
Start: 08/23/24 End: 08/31/29 Due: 08/31/30

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04191187 Org: User:
Start: 12/06/19 End: 02/14/24 Due: 02/14/25

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Phase: N/A Priority: Normal
NCT ID: NCT05015426 Org: User:
Start: 03/21/22 End: 09/30/26 Due: 09/30/27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Phase: N/A Priority: Normal
NCT ID: NCT06511882 Org: User:
Start: 11/07/24 End: 08/31/28 Due: 08/31/29

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02780609 Org: User:
Start: 07/20/17 End: 02/23/21 Due: 02/23/22

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT03072043 Org: User:
Start: 05/18/17 End: 12/08/21 Due: 12/08/22

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase: N/A Priority: Normal
NCT ID: NCT01701674 Org: User:
Start: 10/09/12 End: 09/08/25 Due: 09/08/26

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04052334 Org: User:
Start: 09/27/19 End: 06/16/23 Due: 06/16/24

Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention

Phase: N/A Priority: Normal
NCT ID: NCT02592447 Org: User:
Start: 09/29/15 End: 09/02/21 Due: 09/02/22

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005798 Org: User:
Start: 07/31/95 End: 07/31/07 Due: 07/31/08

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT06597565 Org: User:
Start: 09/25/24 End: 08/23/28 Due: 08/23/29

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Phase: N/A Priority: Normal
NCT ID: NCT02588339 Org: User:
Start: 03/04/16 End: 07/13/21 Due: 07/13/22

Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN)

Phase: N/A Priority: Normal
NCT ID: NCT04092764 Org: User:
Start: 01/23/20 End: 11/11/21 Due: 11/11/22

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase: N/A Priority: Normal
NCT ID: NCT01841021 Org: User:
Start: 04/30/14 End: 06/30/16 Due: 06/30/17

Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes

Phase: N/A Priority: Normal
NCT ID: NCT02416011 Org: User:
Start: 03/31/15 End: 06/30/19 Due: 06/30/20